Role of Some Biochemical Indices for Prediction of Acute Kidney Injury in Intensive Care Unit Patients in Upper Egypt

January 19, 2025 updated by: Ehdaa Ahmed Sanosy Mohamed, Assiut University
  1. We will investigate the relation between the triglyceride-glucose index and the development of AKI in ICU.
  2. To detect whether the TGI is a predictor of poor outcome (requirement of renal replacement therapy, or 14-day in-hospital mortality, and length of hospital stay) in ICU.
  3. Compare TGL, Neutrophil-to-lymphocyte ratio, and clinical score (sequential organ failure assessment SOFA score) as predictors of poor outcome in ICU.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Acute kidney injury (AKI) is a common clinical syndrome with a broad aetiological profile. It complicates about 5% of hospital admissions and 30% of admissions to intensive care units (ICU). During last 20 years has been a significant change in the spectrum of severe AKI such that it is no longer mostly a single organ phenomenon but rather a complex multisystem clinical problem. mortality from AKI, when part of MOF, remains over 50%.

In the past few decades, the understanding of AKI has greatly improved, but early diagnosis remains a great challenge. The performance of traditional kidney function index and serum creatinine is very limited for the early diagnosis of acute kidney injury The triglyceride glucose index (TGI) has been suggested as a useful marker of insulin resistance. Previous studies have shown that TGI is associated with many diseases, but no study has examined the relationship between TGI and Aki .

the primary objective of the present study was to investigate the relationship between TGI and Aki.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Ehdaa Ahmed Sanosy a Ehdaa Sanosy, Resident in Internal Medicine
  • Phone Number: +20 1122322491
  • Email: ehdaa00sanosy@gmail.com

Study Contact Backup

  • Name: Prof. Dr. Lobna Farrag El Toony f El Toony, Professor of Internal Medicine
  • Phone Number: +01005571004
  • Email: leltoni@yahoo.com

Study Locations

  • Egypt
      • اسيوط, Egypt
        • جامعة اسيوط

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The selected patients will be with the following inclusion criteria:

Patients admitted to ICU within 24 hours

Description

Inclusion Criteria:

  • The selected patients will be with the following inclusion criteria:

Patients admitted to ICU within 24 hours

Exclusion Criteria:

  • We will exclude those with any of the following:

    1. Patients diagnosed more than 24 hours.
    2. Patients with missing data of triglyceride or glucose.
    3. Patients <18years old.
    4. patient with advanced liver disease and chronic kidney disease with or without dialysis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
TGI
Time Frame: baseline
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Study Director: Dr. Taghreed Sayed Mohamed Meshref s Meshref, Lecturer of Critical care med, Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2025

Primary Completion (Estimated)

May 30, 2025

Study Completion (Estimated)

June 30, 2025

Study Registration Dates

First Submitted

December 22, 2024

First Submitted That Met QC Criteria

January 19, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 19, 2025

Last Verified

December 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • prediction of AKI in icu

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Kidney Injury

Clinical Trials on biochemical indices

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe